Table 4.

Ranking findings for all outcomes at class level

Class‐level interventions	SUCRA PASI 90	Rank PASI 90	SUCRA SAE	Rank SAE	SUCRA PASI 75	Rank PASI 75	SUCRA AE	Rank AE	SUCRA PGA	Rank PGA	SUCRA QoL	Rank QoL
Anti‐IL12/23	85.7	2	53.9	3	85.0	2	57.0	3	83.8	2	75.7	3
Anti‐IL17	100.0	1	21.0	8	99.6	1	14.1	6	99.9	1	95.4	1
Anti‐IL23	71.3	3	39.6	5	72.2	3	78.7	2	73.1	3	83.4	2
Anti‐TNF alpha	56.4	4	39.2	6	57.4	4	47.5	5	57.5	4	58.4	4
Other biologics	26.3	6	68.2	2	17.0	7	_	_	16.6	7	15.5	7
Small molecules	41.5	5	45.4	4	42.7	5	7.9	7	42.0	5	40.4	5
Conventional systemic treatments	18.7	7	94.8	1	26.0	6	50.8	4	27.1	6	30.8	6
Placebo	0	8	38.0	7	0	8	94.0	1	0	8	0.4	8

AE: adverse events; FAEs: fumaric acid esters; PGA: Physician Global Assessment; QoL: Specific quality of life scale; SAE: serious adverse events